Skip to main content

Table 1 Association between clinical-pathological features and treatment received (N = 60)

From: Role of gonadotropin-releasing hormone analogues in metastatic male breast cancer: results from a pooled analysis

Characteristic With GnRH N (%) Without GnRH N (%) p value*
Age    
 Median 64 63 0.79
 Range 24–82 29–76  
ECOG PS    
 Median 1 1 0.88
 Range 0–2 0–2  
Hormone receptor status    
 Positive 32 (86.5) 19 (82.6) 0.99
 Negative 2 (5.5) 2 (8.7)  
 Unknown 3 (8) 2 (8.7)  
Adjuvant systemic therapy    
 Yes 19 (51) 10 (43.5) 0.60
 No 18 (49) 13 (56.5)  
Prior therapy for metastatic disease    
 Yes 9 (24) 7 (30.5) 0.99
 No 28 (76) 16 (69.5)  
Subsequent lines of CT    
 Median 1 1 0.72
 Range 1–2 1–2  
Subsequent lines of HT    
 Median 1 1 0.85
 Range 1–3 1–3  
Dominant disease site    
 Viscera 24 (64.9) 14 (60.8)  
 Bone 9 (24.3) 8 (34.8) 0.98
 Soft-tissue 4 (10.8) 1 (4.4)  
Number of disease sites    
 1 11 (29.7) 10 (43.4)  
 2 21 (56.7) 9 (39.1) 0.99
  ≥ 3 5 (13.6) 4 (17.5)  
  1. ECOG PS: Eastern Cooperative Oncology Group Performance Status; CT: chemotherapy; HT: hormone therapy
  2. *Fisher exact test